No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Theravance is the latest company to be caught in a web created by FDA's ongoing examination of its approach to evaluating new antibiotics. In a move widely anticipated by Wall Street analysts and Theravance alike, FDA sent a "complete response" letter Nov. 27 asking the drug maker for additional data and analyses for its telavancin (Vibativ) application for nosocomial pneumonia
You may also be interested in...
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area